esomeprazole + naproxen: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
esomeprazole + naproxen: clinical details
Prescribing considerations
- Confirm that a fixed-strength combination is appropriate; use separate components if lower naproxen exposure is required.
- Review benefit and gastrointestinal, renal and cardiovascular risk regularly, particularly in older adults.
- Exclude malignancy when alarm symptoms such as dysphagia, weight loss, recurrent vomiting, haematemesis or melaena are present.
- Avoid concurrent NSAIDs and assess interacting antithrombotic, renal and CYP2C19-related medicines.
Contraindications and cautions
- Hypersensitivity to either component, excipients or substituted benzimidazoles
- Previous aspirin- or NSAID-induced asthma, urticaria or allergic reaction
- Active peptic ulceration or gastrointestinal, cerebrovascular or other bleeding
- Severe renal impairment, severe hepatic impairment or severe heart failure
- Third trimester of pregnancy
- Concurrent atazanavir or nelfinavir
Monitoring
- Renal function in renal impairment, older adults, volume depletion, heart failure or use with diuretics, ACE inhibitors or angiotensin receptor blockers
- Blood pressure, oedema and signs of heart failure
- Hepatic function where impairment is present
- Haemoglobin or bleeding indicators when clinically warranted
- Magnesium during prolonged therapy in patients also using digoxin or medicines that lower magnesium
- Ongoing need and adverse effects during long-term treatment
Clinical pharmacology
The formulation provides immediate esomeprazole release followed by delayed, enteric-coated naproxen release. Naproxen inhibits cyclo-oxygenase-dependent prostaglandin synthesis; esomeprazole irreversibly inhibits gastric parietal-cell H+/K+-ATPase.
Formulation and product differences
- A sequential-delivery modified-release tablet rather than two independently adjustable products.
- The tablet must remain intact to preserve its release characteristics.
- Delayed naproxen release makes the product unsuitable for acute pain requiring rapid onset.
- The fixed formulation cannot provide a lower naproxen strength.
esomeprazole + naproxen preparations and strengths
Modified-release tablet
Route: Oral
Strengths: 500 mg + 20 mg
esomeprazole + naproxen interactions
Check all prescribed, non-prescription and herbal products before treatment. Important interactions include:
Other NSAIDs, including ibuprofen and COX-2 inhibitors
Combining them increases gastrointestinal, kidney and other NSAID-related risks and should be avoided.
Warfarin, heparins and other anticoagulants
Bleeding risk can increase; warfarin may require closer INR monitoring.
Clopidogrel
Esomeprazole can reduce formation of clopidogrel’s active metabolite, so concomitant use is discouraged.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.